Parenteral Manual

Adalimumab (NON-FORMULARY)

Disclaimer: Official controlled document is the CHEO online copy. It is the responsibility of user to ensure that any paper copy version is the same as the online version before use.

Alternate Name(s): 
HUMIRA
Classification: 
Disease-modifying Antirheumatic drug, Tumor Necrosis Factor (TNF) - Blocking agent
Original Date: 
September 2008
Indications: 
  • Active rheumatoid arthritis (moderate-severe) and active psoriatic arthritis; may be used alone or in combination with disease-modifying antirheumatic drugs (DMARDs) 
  • Ankylosing spondylitis
  • Active Crohn's disease (moderate - severe) in patients with inadequate response to conventional treatment, or patients who have lost response to or are intolerant of infliximab
  • Juvenile idiopathic arthritis (moderate - severe)
Reconstitution and Stability: 
  • Available as 40 mg/0.8 mL vial and 40 mg/0.8 mL prefilled syringe
  • Refrigerate  -do not freeze
  • Protect from light
  • Needle cap of prefilled syringe may contain latex
Compatibility: 

-Solutions Compatible:  No Information

-Additives/Above Cassette Compatible:  No information

-Y-site Compatible:  No information

Incompatible:  No information

Administration: 

(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)

SC YES
Rotate injection sites. 
Do not administer to skin which is red,tender,bruised, or hard
IM NO
IV Push NO
IV Intermittent Infusion NO
IV Continuous Infusion NO
Dosage: 

(For neonatal dosages, refer to Neonatal IV Drug Manual.)

Pediatric:

- Juvenile idiopathic arthritis: Children  >4 years

  • 15 kg to <30 kg: 20 mg every other week
  • >30 kg: 40 mg every other week

Adults:

-Rheumatoid arthritis:

  • 40 mg every other week; may be administered with other DMARDs; patients not taking methotrexate may increase dose to 40 mg every week

-Ankylosing spondylitis, psoriatic arthritis:

  • 40 mg every other week

-Crohn's disease:

  •  Initial: 160 mg given as 4 injections on day 1 or over 2 days, then 80 mg 2 weeks later (day 15); Maintenance: 40 mg every other week beginning day 29
Potential hazards of parenteral administration: 
  • Local reactions:  erythema, itching, hemorrhage, pain, swelling
  • Headache, nausea, abdominal pain, flu-like symptoms
  • Allergic reactions:  rash , anaphylaxis (rare) -medications for treatment of hypersensitivity reactions should be available for immediate use
  • Increased susceptibility to  infections  including tuberculosis, invasive fungal infections, & other opportunistic infections (Histoplasma, Aspergillus, & Nocardia)
  • Rare cases of autoimmune disorder, including lupus-like syndrome reported
Notes: 
  • Perform tuberculin skin test prior to initiating therapy
  • DO NOT administer live vaccines concurrently  - bring immunizations up to date before initiating therapy
  • Use with caution in patients with chronic infection, history of recurrent infection or predisposition to infection.  DO NOT give to patients with active chronic or localized infection,  monitor closely if a new infection develops  while on treatment, and discontinue treatment if  a serious infection or lupus-like syndrome develops

The information contained on this website is provided for informational purposes only, as a guide to assist physicians, nurses and other healthcare providers in deciding on the appropriate care required for a particular patient. At all times, physicians, nurses and other healthcare providers must exercise their independent clinical judgment, based on their knowledge, training and experience, taking into account the specific facts and circumstances of each patient, when deciding on the appropriate course of investigation and/or treatment to recommend in a particular clinical situation.

CHEO has made every effort to ensure that the information contained on this website is as current and accurate as possible. However, changes can occur due to ongoing research and the constant influx of new information. Where possible, hospitals and healthcare practitioners should verify the information before acting on it.

Reliance on any information in this website is at the user's own risk. CHEO is not responsible or liable for any harm, loss or other consequences from the use or misuse of the information on this website.